Abstract: There is provided a method of classifying a biological status of an individual. The method comprising: obtaining a biological sample from a patient; obtaining health-related information from the patient, said information including patient gender; analysing the sample to identify a quantity of each of 2 or more endogenous analytes in the sample; comparing the analyte quantities to reference data from healthy individuals to classify the patient as healthy, pre-diseased, at risk of disease or diseased for at least one health-related condition. The reference data includes data derived from a group of biological samples of individuals having the same gender as the patient and not having a need for medical treatment for a disease or illness, each biological sample of the group of biological samples having been analysed by the same process as used to analyse the patient sample, the process being monitored to maintain a predetermined level of consistency.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and RCS families. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: The present invention provides an in vitro method for determining the resistance or sensitivity of a cell line or patient sample to a deoxyribonucleoside kinase-dependent drug, wherein the method comprises the steps of: (i) treating a patient sample or cell line, or a portion thereof, with a deoxyribonucleoside kinase-dependent drug; (ii) lysing the cells of the patient sample or cell line from step (i); (iii) optionally, mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for deoxyribonucleoside kinase; (iv) mixing a portion of the cell lysate from (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase and a deoxyribonucleoside kinase transcription promoter; (v) mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase, a deoxyribonucleoside kinase transcription promoter and a dephosphorylating agent

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and RCS families. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: The invention describes a practical and robust multi-antibody approach to the sensitive immunodetection and determination of the drug of abuse m-chlorophenyl piperazine (mCPP). The invention also describes methods and kits for mCPP detection in an in vitro sample.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: The invention describes a method for monitoring and detecting non-therapeutic, therapeutic and toxic concentrations of aspirin in individuals which uses the urinary salicylic acid to salicyluric acid ratio.

Abstract: The invention describes a practical and robust multi-antibody approach to the sensitive immunodetection and determination of the drug of abuse m-chlorophenyl piperazine (mCPP). The invention also describes methods and kits for mCPP detection in an in vitro sample.

Abstract: The present invention provides an in vitro method for determining the resistance or sensitivity of a cell line or patient sample to a deoxyribonucleoside kinase-dependent drug, wherein the method comprises the steps of: (i) treating a patient sample or cell line, or a portion thereof, with a deoxyribonucleoside kinase-dependent drug; (ii) lysing the cells of the patient sample or cell line from step (i); (iii) optionally, mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for deoxyribonucleoside kinase; (iv) mixing a portion of the cell lysate from (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase and a deoxyribonucleoside kinase transcription promoter; (v) mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase, a deoxyribonucleoside kinase transcription promoter and a dephosphorylating agent